Core Viewpoint - PetMed Express, Inc. has announced preliminary second quarter fiscal year 2026 results, indicating a significant decline in net sales compared to the previous year, and has filed a Notification of Late Filing with the SEC due to delays in filing its Form 10-Q [1][2]. Financial Performance - For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million, a decrease from $58.0 million in the prior year period [2]. - For the six months ended September 30, 2025, net sales are estimated to range from $94.5 million to $95.6 million, down from $124.3 million in the prior year period [2]. - The company reported $36.1 million in cash and no debt as of September 30, 2025 [4]. Compliance and Regulatory Issues - On November 12, 2025, the company received a notice from Nasdaq indicating non-compliance due to delays in filing its Quarterly Reports for the periods ended June 30, 2025, and September 30, 2025 [5]. - The company must submit an update to its original plan to regain compliance by November 28, 2025, following a previous submission on September 2, 2025 [6]. - The notice does not have an immediate effect on the listing of the company's common stock on Nasdaq [6]. Operational Challenges - The company is currently unable to provide estimates for operating income or net income for the three- and six-month periods ended September 30, 2025, due to ongoing analysis of a potential goodwill impairment charge [3]. - The company is working diligently to complete and file its Q1 10-Q and Q2 10-Q as soon as possible to regain compliance with Nasdaq listing standards [7]. Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, offering a range of pet health solutions through its brands, including PetCareRx [8]. - The company is licensed across all 50 states and focuses on providing value, convenience, and care to pet owners [8].

Core Viewpoint - PetMed Express, Inc. has appointed James LaCamp to its Board of Directors, effective immediately, and he will become Chair of the Audit Committee on October 30, 2025, enhancing the company's financial governance and oversight capabilities [2][3]. Board Composition and Changes - The appointment of James LaCamp is part of PetMed's ongoing board refreshment strategy, which aims to build a board of independent and highly qualified directors to support profitable revenue growth and shareholder value creation [3][4]. - Since fiscal Q4 2024, notable changes to the board include Leslie C. G. Campbell becoming Chair of the Board, and the appointments of Justin Mennen, Leah Solivan, and Peter Batushansky, resulting in a board of six directors, five of whom are independent [3][4]. James LaCamp's Background - James LaCamp brings nearly 20 years of experience in finance, accounting, and corporate strategy, having served as Chief Financial Officer at various technology companies and as an Audit Partner at Deloitte & Touche LLP [5][6][7]. - Currently, LaCamp is the Chief Financial Officer of Skydio, overseeing all financial operations, and has held leadership roles in other technology firms, contributing to financial strategy and operations [7][8]. Company Overview - PetMed Express, founded in 1996, is a pioneer in the direct-to-consumer pet healthcare sector, offering a range of pet health solutions through its online pharmacy, licensed across all 50 states [10]. - The company focuses on value, convenience, and care, empowering pet parents to support the health of their pets [10].

Core Viewpoint - PetMed Express, Inc. has announced preliminary financial results for the fourth quarter and fiscal year 2025, indicating a significant decline in net sales and an increase in net loss compared to the previous year [1][2][3]. Financial Performance - For the fiscal fourth quarter ended March 31, 2025, net sales are estimated to be between $51.1 million and $53.1 million, down from $66.5 million in the prior year [2]. - The estimated net loss for the fourth quarter is between $9.9 million and $10.4 million, compared to a net loss of $5.0 million in the prior year [2]. - For the fiscal year ended March 31, 2025, net sales are estimated to range from $231.6 million to $233.6 million, a decrease from $281.1 million in the prior year [3]. - The estimated net loss for the fiscal year is between $4.5 million and $5.0 million, an improvement from a net loss of $7.5 million in the prior year [3]. - The net loss includes a tax expense impact of $6.4 million due to a valuation allowance on the Company's net deferred tax assets [2][3]. Cash Position - As of March 31, 2025, the Company reported $54.7 million in cash and no debt [4]. Filing Status - The Company has filed Form 12b-25 with the SEC, indicating it is unable to file its Annual Report on Form 10-K within the prescribed time period, but expects to do so by July 1, 2025 [1][5].

Core Viewpoint - PetMed Express, Inc. will hold a conference call to discuss its financial results for the fourth quarter and full fiscal year ended March 31, 2025, on June 10, 2025 [1][2]. Company Overview - PetMed Express, Inc., operating as PetMeds, is a pioneer in the direct-to-consumer pet healthcare sector, founded in 1996 [3]. - The company is a licensed national online pharmacy across all 50 states, providing a range of pet health solutions including pharmaceuticals, compounded medications, and OTC supplements [3]. - PetMeds aims to empower pet owners to enhance the health and longevity of their pets through value, convenience, and care [3]. Conference Call Details - The conference call is scheduled for June 10, 2025, at 4:30 PM Eastern Time, with a question-and-answer session following the management's presentation [2]. - Participants are encouraged to dial in 5-10 minutes prior to the start time using the provided U.S. and international numbers [2]. - A telephonic replay of the conference call will be available after 7:30 PM Eastern Time on the same day until June 24, 2025 [2][3].